From Failed Attempts to Platform
Racaniello's memory of RNA vaccines begins with disbelief: early attempts did not work, then researchers began asking whether RNA itself could be delivered. CNBC's reporting shows the payoff in manufacturing: Moderna and Pfizer built messenger RNA platforms that could scale quickly. The spoken record captures a technical shift becoming an industrial one, with clinical trials and HIV work preceding COVID.






